Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020
Pharmacokinetic and pharmacodynamic characteristics of HFA and CFC pMDI formulations of budesonide Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
Ipratropium bromide HFA propellant inhaler has equivalent safety and efficacy to the marketed CFC propellant inhaler in bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
HFA vs CFC beclomethasone dipropionate – comparative effectiveness in asthma management Source: Eur Respir J 2006; 28: Suppl. 50, 498s Year: 2006
The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
Comparison of the efficacy and safety of budesonide administered via Clickhaler® or Turbuhaler® Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Evaluation of the systemic pharmacodynamic effects of two HFA formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/250 mcg Source: International Congress 2017 – Inhalers and their use Year: 2017
A comparative study of the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of salmeterol HFA and CFC MDI inhalers in healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Efficacy and safety of budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) using co-suspension delivery technology compared to monocomponents and an active comparator in COPD Source: International Congress 2018 – Pharmacological management of COPD Year: 2018
Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003
Safety of beclomethasone HFA (HFA BDP) pMDI compared with beclomethasone CFC pMDI (CFC BDP) over 12 weeks Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005
Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Assessment of the suitability of filters for use in clinical studies with an HFA fluticasone propionate pressurized metered dose inhaler (pMDI) and a valved holding chamber (VHC) Source: Annual Congress 2011 - Lung function today and tomorrow II Year: 2011
Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008
Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
Systemic activity of beclometasone dipropionate HFA and CFC formulations in metered dose inhalers assessed by knemometry Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009